Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04524273 · ClinicalTrials.gov registry record · Phase 3
Myasthenia Gravis Inebilizumab Trial
A Phase 3 study of Myasthenia Gravis, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 238
- Enrollment target
- 20
- Study locations
NCT04524273 is a Phase 3 study of Myasthenia Gravis that is active but no longer recruiting, run by Amgen. The registered enrollment target is 238 participants, above the 184-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04524273, a Phase 3 study of Myasthenia Gravis, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 238 participants
- Enrollment target
- 20
- Study locations
Study Summary
Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
Conditions Studied
Interventions
- DRUG IV Placebo
- DRUG inebilizumab
Study Locations (20)
Other
- Viela Bio Investigative Site - 2001 - Buenos Aires
- VielaBio Investigative Site - 2002 - Buenos Aires
- Viela Bio Investigative Site - 2003 - Buenos Aires
- Viela Bio Investigative Site - 5203 - Grodno
Ohio
- Viela Bio Investigative Site - 1025 - Canton
- Viela Bio Investigative Site - 1001 - Cincinnati
- Viela Bio Investigative Site - 1009 - Columbus
Texas
- Viela Bio Investigative Site - 1019 - Austin
- Viela Bio Investigative Site - 1003 - Houston
- Viela Bio Investigative Site - 1014 - San Antonio
California
- Viela Bio Investigative Site - 1015 - Orange
Connecticut
- Viela Bio Investigative Site - 1002 - New Haven
District of Columbia
- Viela Bio Investigative Center - 1024 - Washington D.C.
Florida
- Viela Bio Investigative Site - 1005 - Tampa
Kansas
- Viela Bio Investigative Site - 1012 - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2027-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524273
The ClinicalTrials.gov registry entry for NCT04524273 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 184-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (29% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which IV Placebo is the first listed.
NCT04524273 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT04524273 about?
NCT04524273 is a clinical study titled "Myasthenia Gravis Inebilizumab Trial". Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
What is the current status of trial NCT04524273?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2020-10-15. Estimated completion is 2027-11-29.
What conditions does trial NCT04524273 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT04524273?
The interventions under investigation include: IV Placebo (DRUG), inebilizumab (DRUG).
Who is sponsoring clinical trial NCT04524273?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04524273 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
-
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
COMPLETED · Phase 3
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.